Fisher A M, Rucker N, Wong S, Gomer C J
Clayton Ocular Oncology Center, Childrens Hospital Los Angeles, CA, USA.
J Photochem Photobiol B. 1998 Feb;42(2):104-7. doi: 10.1016/s1011-1344(97)00130-9.
Tumor sensitivity to cancer therapies may be modulated by the p53 status of the malignant cells. Generally, tumors retaining wild-type p53 are more sensitive to radiotherapy and some chemotherapeutic agents than are tumors with either a mutated or deleted p53 phenotype. The role of p53 in the responsiveness to PDT as a cancer treatment is clinically unknown. In the current study, we evaluated the photosensitivity of two human colon carcinoma cell lines, one expressing wild-type p53 protein and the other expressing mutant p53. Wild-type p53 cells were found to be significantly more sensitive to Photofrin-mediated photodynamic treatment measured by clonogenic assay. Uptake of the photosensitizer was equivalent for both cell lines. Interestingly, sensitivity of the colon carcinoma cell lines to ionizing radiation was similar. These two cell lines represent a useful model for examining p53 involvement in the cellular response to PDT-mediated oxidative stress.
肿瘤对癌症治疗的敏感性可能受恶性细胞的p53状态调节。一般来说,保留野生型p53的肿瘤比具有p53突变或缺失表型的肿瘤对放疗和某些化疗药物更敏感。p53在作为癌症治疗的光动力疗法(PDT)反应性中的作用在临床上尚不清楚。在当前研究中,我们评估了两个人结肠癌细胞系的光敏性,一个表达野生型p53蛋白,另一个表达突变型p53。通过克隆形成试验测定发现,野生型p53细胞对卟吩姆钠介导的光动力治疗明显更敏感。两种细胞系对光敏剂的摄取相当。有趣的是,结肠癌细胞系对电离辐射的敏感性相似。这两种细胞系是用于研究p53参与细胞对PDT介导的氧化应激反应的有用模型。